Celgene Corp (CELG) 85.31 $CELG
IBD 50 Ends Week Lower But Skyworks Soars
at Investor's Business Daily - Mon Jul 21, 5:47PM CDT
The IBD 50 fell for a second straight week amid the market's recent turbulence as biotech stocks sold off. But many leading stocks continue to hold up well, and few have flashed sell signals. The index of top growth stocks fell 0.6% for the week,...
Final Glance: Biotechnology companies
AP - Mon Jul 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Midday Glance: Biotechnology companies
AP - Mon Jul 21, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
SmarTrend Watching for Potential Rebound in Shares of Celgene After 3.39% Loss
Comtex SmarTrend(R) - Thu Jul 17, 4:35PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Set to Possibly Rebound After Yesterday's Selloff of 3.39%
Comtex SmarTrend(R) - Thu Jul 17, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Shares Up 15.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Thu Jul 17, 11:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 15.53% as of today's recent price of $85.42.
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
IBD 50 Ends Week Lower But Skyworks Soars
at Investor's Business Daily - Mon Jul 21, 5:47PM CDT
The IBD 50 fell for a second straight week amid the market's recent turbulence as biotech stocks sold off. But many leading stocks continue to hold up well, and few have flashed sell signals. The index of top growth stocks fell 0.6% for the week,...
Final Glance: Biotechnology companies
AP - Mon Jul 21, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Biogen Shares Rebound As Street Has A Change Of Heart
at Investor's Business Daily - Mon Jul 21, 3:09PM CDT
Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. The No. 3 biotech by market...
Yellen Hates Biotech Stocks! Should You?
Brian Orelli, The Motley Fool - Motley Fool - Mon Jul 21, 1:01PM CDT
Federal Reserve Chairwoman Janet Yellen thinks your small-cap biotech is overvalued. The Fed's Monetary Policy Report, released on July 15, had this to say: [V]aluation metrics in some sectors do appear substantially stretched -- particularly...
Midday Glance: Biotechnology companies
AP - Mon Jul 21, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Early Glance: Biotechnology companies
AP - Mon Jul 21, 10:38AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Facebook, Gilead Headline IBD 50's Top 5 Earnings
at Investor's Business Daily - Sat Jul 19, 7:02AM CDT
With earnings season in full force, investors should focus on the very best companies. The elite IBD 50 ranks top-rated growth stocks, factoring in strong relative price strength and top fundamentals. The IBD 50 has several companies reporting...
SmarTrend Watching for Potential Rebound in Shares of Celgene After 3.39% Loss
Comtex SmarTrend(R) - Thu Jul 17, 4:35PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Set to Possibly Rebound After Yesterday's Selloff of 3.39%
Comtex SmarTrend(R) - Thu Jul 17, 4:34PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $82.90 to a high of $86.19. Yesterday, the shares fell 3.4%, which took the trading range below the 3-day low of $85.60 on volume of 5.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Shares Up 15.5% Since SmarTrend's Buy Recommendation (CELG)
Comtex SmarTrend(R) - Thu Jul 17, 11:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 3 months, Celgene has returned 15.53% as of today's recent price of $85.42.
Cramer: The Tell of When to Sell
at The Street - Thu Jul 17, 9:40AM CDT
If you're worried about these moves, it's time to cash out.
Biotech Stock Roundup: AbbVie Woos Shire with Revised Offer, Sarepta Slips on Eteplirsen Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 16, 8:49AM CDT
Focus last week remained on AbbVie's (ABBV) attempts to acquire Shire (SHPG) - the company came back with a revised offer which could very well be accepted by Shire.
